Nerve growth and regeneration.
Born from the collective ambition of industry veterans and technology innovators.
Our mission is simple — develop a drug that works. We recognize that there are no treatments for peripheral neuropathy today. We strive to impact the lives of today’s patients heavily burdened by this disease.
Fueled by over $40 million in U.S. and Canadian government grants, we are advancing regenerative treatments from the lab to patients worldwide.
$40m+
Received $40M+ in grants from the United State and Canadian government to solve this problem.
* We are actively assesing other licensing collaborations.
Paul is the chairman of the Department of Pharmacology & Therapeutics as well as a professor at the University of Manitoba. He is also the director of Division of Neurodegenerative Diseases at the St. Boniface Hospital Research Centre, Winnipeg. He has worked for 30 years on nerve cell biology and in the diabetic neuropathy field studying the etiology of the disease using in vitro and in vivo approaches. He invented the in vitro drug screen assay utilizing primary sensory neurons that identified the drugs currently under investigation.
Paul Fernyhough PhD
Co-Founder
Nigel is the professor of pathology at the University of California San Diego and has studied peripheral neuropathy since his undergraduate studies with one of the scientific founders of the field, David Tomlinson, in 1983. He has been involved in the preclinical/clinical development of multiple therapeutic programs and is a KOL for companies engaged in drug development. He also served as the lead preclinical contactor to the NIH NIDDK-RAID program and is a member of the executive committee of the EASD Neurodiab Study Group.
40+
Over 40 years in drug development for Peripheral Neuropathy.
10+
Contributed to more than ten different drugs or drug classes/approaches.
